Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13146450 | 0.86 | LTA4H (0.51) | LTA4HBRD4TP53SMN1; SMN2GAA | |
| SCHEMBL3283655 | 0.85 | BRD4 (0.46) | LTA4HBRD4TP53SMN1; SMN2GAA | |
| SCHEMBL30804513 | 0.85 | LTA4H (0.50) | LTA4HBRD4TP53SMN1; SMN2GAA | |
| SCHEMBL17915383 | 0.85 | LTA4H (0.50) | LTA4HBRD4TP53SMN1; SMN2GAA | |
| SCHEMBL16418027 | 0.85 | LTA4H (0.56) | LTA4HBRD4TP53SMN1; SMN2GAA | |
| SCHEMBL28982182 | 0.85 | LTA4H (0.50) | LTA4HBRD4TP53SMN1; SMN2GAA | |
| SCHEMBL8518749 | 0.83 | BCHE (0.50) | LTA4HBRD4TP53SMN1; SMN2GAA | |
| SCHEMBL23375191 | 0.82 | SMN1; SMN2 (0.52) | LTA4HTP53SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL22675502 | 0.82 | SMN1; SMN2 (0.52) | LTA4HTP53SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL16556615 | 0.82 | SMN1; SMN2 (0.52) | LTA4HTP53SMN1; SMN2GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592460-B2 | Amino-pyridine derivatives as S1P1 /EDG1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-26 | — | — | US | disclosed |
| US-20100087417-A1 | AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-08 | — | — | US | disclosed |
| EP-2125797-A1 | AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008114157-A1 | AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087417-A1 | AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR4 | LTA4H 767/4885BRD4 387/4885TP53 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.